Hope is a job, not an amorphous entity that's always beyond our eager grasp. This reality was underscored recently when I enrolled in the Family Healing Together course, "Recovering our Hope."
I used to have a misconception about hope. I thought it was something that you went to church to pray to get, or something that people say when what they really mean is that hope is lost. "Well, there's always hope," people will say, and you know right then and there that the hope vessel is sunk.
No sir. Hope is a job that you get up every day for and go to work for. You learn how to have hope and once you do, you learn how to practice it, manage it, and adapt it to your own situation. Hold it, examine it, work with it.
What does it look like? Well, here's an example. Maybe you are worried that your son or daughter will never, never, ever, be able to put the pieces of his or her life together, because some part of his or her recent behavior has caused you to doubt. Maybe it's yet another missed appointment or not being able to get out of bed in the morning. Maybe it's a lack of concrete achievements or crippling self-doubt. Maybe it's all of that or something else.
So, you start by reframing - turning your own negative perceptions into something positive, because if you look closely, you will see that your relative is making choices and perhaps even moving forward in some crazy way that eludes you. You may realize that there is something you can offer them that helps them flourish. It comes from YOU.
You get down on your hands and knees and blow on the embers when the flicker of hope is dying. Maybe all it takes is a post-it note, or a rigorous mental exercise to focus on the positive and ignore the negatives. One thing I do is to keep returning to my read what my role models, people who also share a positive perspective, say.
Here's one such positive perspective from the course, which is post-it note worthy:
"Suspend judgement and consider the possibility that even your most outlandish
hopes can not only nourish you, but can also help you flourish."
Wednesday, November 20, 2013
Monday, November 11, 2013
Sockpuppets, astroturfing and anti-stigma campaigns
Vocabulary words for today: Sockpuppet, Astroturfing
Help me add more search words to my limited search vocabulary. Pharma's public relations teams are always finding new ways to convince the public that demand for its products is grassroots. Anti-stigma campaigns are one example. In the 1990s Eli Lilly channeled money through the The World Psychiatric Association and NAMI to launch an anti-stigma campaign. The "crowdfunding" concept today is supposed to be grassroots fundraising, but there is a huge potential for abuse, e.g. astroturfing fake donations.
Pharmaceutical Industry Agenda Setting in Mental Health
Policies
Help me add more search words to my limited search vocabulary. Pharma's public relations teams are always finding new ways to convince the public that demand for its products is grassroots. Anti-stigma campaigns are one example. In the 1990s Eli Lilly channeled money through the The World Psychiatric Association and NAMI to launch an anti-stigma campaign. The "crowdfunding" concept today is supposed to be grassroots fundraising, but there is a huge potential for abuse, e.g. astroturfing fake donations.
Pharmaceutical Industry Agenda Setting in Mental Health
Policies
Richard Gosden and Sharon Beder
Citation: Richard Gosden and Sharon Beder,
'Pharmaceutical Industry Agenda Setting in Mental Health Policies', Ethical
Human Sciences and Services 3(3) Fall/Winter 2001, pp. 147-159.
The use of sophisticated public relations techniques for
setting political agendas has become a standard practice in most advanced
democracies. The consequences are slowly becoming apparent. The system of
representative democracy is being reshaped into a new kind of "managed
corporatocracy" in which public opinion and government policy are custom-made
products that can be shaped, packaged and sold by skilled public relations
experts.
Setting the Agenda for Policy on Schizophrenia
An extended campaign to set the policy making agenda in regard
to schizophrenia offers a particularly good illustration of how these tactics
work. All of the pharmaceutical companies involved in this agenda setting
campaign have introduced new, atypical neuroleptic drugs for schizophrenia
treatment onto the market over the past decade. These new drugs had been
developed for two main reasons: 1) patents for the older generation of drugs
were expiring and cheap generics were coming onto the market; and 2) the older
generation of schizophrenia drugs had fallen into disrepute for being both
ineffective and dangerous. However, in introducing the new drugs the
pharmaceutical companies were confronted by two difficult public relations
problems: (a) the new drugs are many times more expensive than the older drugs
and, (b) according to critics, they are not any more effective or safer than the
old drugs they replace. (Breggin and Cohen, 1999, pp. 76-82).
The pharmaceutical companies wanted to maximize their profits
in what appeared to be a potentially critical environment and a tight market.
They decided the best approach would be to find ways to expand the size of the
market. Hitherto the market for schizophrenia drugs had been restricted by
diagnostic conventions, on the one hand, and civil liberties protections on the
other. Until recently diagnostic conventions generally limited the recognition
of schizophrenia, and therefore the application of neuroleptic drug treatment,
to symptoms which indicate psychosis. The agenda setters determined to expand
the market by breaking this convention and promoting the concept of an
additional pre-psychotic phase of schizophrenia which requires preventive
treatment with their new drugs. To further expand the market they also decided
to wage campaigns to weaken civil liberties protections and thereby increase the
number of people who could be treated involuntarily.
The overall solution was the development of a two-fold public
relations campaign that is still in progress. The first part involves harnessing
support groups for relatives of people suffering from schizophrenia as the
driving force for an advocacy coalition. This has been achieved by carefully
focussed funding of these organizations. (Gosden, 2001, pp. 94-97). Once they
were made dependent on drug company ‘sponsorship’ they could then be used as
public relations front-groups to assist with planting stories in the media about
the efficacy and safety of the new drugs and about claims that schizophrenia has
supposedly been scientifically proven to be a brain disease requiring urgent
drug treatment at the earliest signs. A ready example of this practice can found
at schizophrenia.com (schizophrenia.com, 2001a) which purports to be "A
Not-for-Profit Information, Support and Education Center" representing
consumers. However, schizophrenia.com acknowledges on its web site that it is
funded by Janssen Pharmaceuticals. (Schizophrenia.com, 2001b). The slant on
schizophrenia being promoted by drug company-funded organisations like
schizophrenia.com is intended to impact on governments as expressions of public
interest advocacy and to position the new drugs as preferred methods of
treatment by government mental health services.
An aspect of the campaign involves funding selected psychiatric
researchers to promote the doubtful belief that schizophrenia must be detected
and treated in a pre-psychotic stage to avoid brain deterioration. (Gosden,
2001, pp. 224-247). This line of argument has the potential to vastly expand the
market for schizophrenia drugs and has already led to the development in
Australia of government-sponsored preventive treatment programs for
schizophrenia, which utilize the new drugs.
A key element of the PR strategy involves funding from the drug
company Eli Lilly being channeled through both the World Psychiatric Association
(Rosen et al. 2000) and NAMI (Silverstein, 1999; Oaks, 2000, p. 14) to mount an
anti-stigma campaign. The thrust of the anti-stigma campaign is to advocate for
the elimination of discrimination against people diagnosed with
schizophrenia, so long as they are taking medication.
Meanwhile, in what appears to be a coordinated strategy, the
Treatment Advocacy Center (TAC), which was originally established as branch of
NAMI, has been feeding a very different, but complimentary, line to the media
and the public about the dangerousness of untreated schizophrenia. This
line involves associating untreated schizophrenia with news stories about
violent behavior (Torrey & Zdanowicz, 1999, p. 27A) and promoting wild
hyperbole about the murderous intentions of untreated schizophrenics: "Violent
episodes by individuals with untreated schizophrenia and bipolar disorder have
risen dramatically, now accounting for an estimated 1,000 homicides annually in
the United States" (Treatment Advocacy Center, 2001a). This approach is intended
to send an agenda setting spin in the opposite direction by scaring the public
and impacting on governments as a law and order imperative. The policy intention
with this counter spin is to weaken civil liberties protections in mental health
laws in order to increase the number of people eligible for involuntary
treatment.
Subscribe to:
Posts (Atom)